In Re Relafen Antitrust Litigation
States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.
Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
U.S. et al. v. EchoStar Communications, Corp., et al. No. 1:02CV02138 (D.D.C.)
Federal and State action to enjoin merger of two direct broadcast satellite (DBS) companies. The merging parties abandoned their merger agreement
Nevada v. Merkley & Hankins 1988 WL 247971 (Nev. Dist. Ct.)
Settlement of gasoline price fixing case.
Natural Gas Antitrust Cases I-IV, JCCP No. 4221, et al. (Sup. Ct. of Cal., San Diego 2000)
California, Nevada, Oregon, and Washington investigated El Paso Corporation and other defendants for conspiring to fix the prices of natural gas. In 2003, a $1.5 billion settlement was reached between El Paso Corporation and California, Nevada, Oregon, Washington, other California entities, and various class actions.
Texas v. Zeneca, 1997 U.S. Dist. LEXIS 13153 (N.D. Tex. 1997)
States sought an injunction and monetary damages from Zeneca, Inc. (Zeneca), alleging that the company conspired with distributors of its crop protection chemicals to maintain the resale price of the chemicals.
In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb
Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.
In re Disposable Contact Lens Antitrust Litigation, 2001-1 Trade Cas. (CCH) & 73,150
Plaintiff States sought damages and injunctive relief against the three major contact lens makers and the American Optometric Association. The States alleged that defendants conspired to cut mail order companies and pharmacies out of the market for replacement contact lenses.
In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)
Plaintiff States sought damages and injunctive relief, alleging that defendants entered into an unlawful agreement attempting to delay or prevent the marketing of less expensive generic alternatives to Cardizem CD, a brand name drug used to prevent heart attacks. The Plaintiff States settled for $80 million, the bulk of which was to be used to reimburse purchasers including consumers, insurance companies and other third-party payers for overcharges paid for Cardizem CD between 1998 and 2003.
Maryland et al v. Mitsubishi Electronics America; 1992-1 Trade Cas. (CCH) ¶69,743 (D. Md. 1992)
Plaintiff States sought damages and injunctive relief, alleging that Mitsubishi Electronics America, Inc. (MELA) conspired with its dealers to set or maintain the resale price of its electronics equipment. In the settlement with Plaintiff States, MELA was enjoined from engaging in the alleged conduct and agreed to pay $6 million dollars for administrative costs and to reimburse qualified buyers.
